Related references
Note: Only part of the references are listed.The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer
K. D. Steffensen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2007)
Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)
D. S. Alberts et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2007)
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy- : A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)
Uwe Wagner et al.
GYNECOLOGIC ONCOLOGY (2007)
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer
Edwin M. Posadas et al.
CANCER (2007)
In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway
D. Pils et al.
BRITISH JOURNAL OF CANCER (2007)
Development of an ovarian cancer symptom index - Possibilities for earlier detection
Barbara A. Goff et al.
CANCER (2007)
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling
Peter Mullen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer
Aparna A. Kamat et al.
CANCER RESEARCH (2007)
Ovarian cancer
Nicoletta Colombo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents
Helen M. Coley et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Clinical activity of Pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status
Michael S. Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study
Jeffrey Bell et al.
GYNECOLOGIC ONCOLOGY (2006)
Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer
Bradley J. Monk et al.
GYNECOLOGIC ONCOLOGY (2006)
Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer
David E. Cohn et al.
GYNECOLOGIC ONCOLOGY (2006)
Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma - A retrospective analysis
Jason D. Wright et al.
CANCER (2006)
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions
Alessandro Morabito et al.
ONCOLOGIST (2006)
Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer
Stephen R. D. Johnston et al.
DRUGS OF TODAY (2006)
Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer
Alberto Serrano-Olvera et al.
CANCER TREATMENT REVIEWS (2006)
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers
RL Coleman et al.
GYNECOLOGIC ONCOLOGY (2006)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
DK Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer
LL Siu et al.
CLINICAL CANCER RESEARCH (2006)
2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth
N Takai et al.
CANCER (2005)
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma
JP Delord et al.
ANNALS OF ONCOLOGY (2005)
Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo
MG del Carmen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study
AN Gordon et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic oncology group study
RJ Schilder et al.
CLINICAL CANCER RESEARCH (2005)
Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors
PH Thaker et al.
CLINICAL CANCER RESEARCH (2005)
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer
DB Agus et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68)
S Machida et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines
Q Dai et al.
CLINICAL CANCER RESEARCH (2005)
HER2/neu oncoprotein overexpression in epithelial ovarian cancer: Evaluation of its prevalence and prognostic significance - Clinical study
E Verri et al.
ONCOLOGY (2005)
Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma
SM Apte et al.
CLINICAL CANCER RESEARCH (2004)
Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor α and akt inactivation
D Matei et al.
CLINICAL CANCER RESEARCH (2004)
HER2 expression in cervical cancer as a potential therapeutic target -: art. no. 59
A Chavez-Blanco et al.
BMC CANCER (2004)
Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma
H Lassus et al.
BRITISH JOURNAL OF CANCER (2004)
ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma
H Lassus et al.
GYNECOLOGIC ONCOLOGY (2004)
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines
A Choudhury et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer
JS Nielsen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2004)
被撤回的出版物: The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study (Retracted Article. See vol 96, pg 1021, 2005)
EK Riener et al.
GYNECOLOGIC ONCOLOGY (2004)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-β in ovarian serous carcinoma and normal ovarian surface epithelium
RE Schmandt et al.
CANCER (2003)
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
J Mendelsohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
MA Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Targeted therapy for epithelial ovarian cancer: Current status and future prospects
HT See et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2003)
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma
I Skirnisdóttir et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2001)
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
MJ Piccart et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
